Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 633

1.

Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.

Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M.

Exp Neurol. 2013 Sep;247:45-58. doi: 10.1016/j.expneurol.2013.03.017. Epub 2013 Mar 24.

PMID:
23531432
2.

Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.

Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M.

Neurobiol Dis. 2013 Aug;56:47-58. doi: 10.1016/j.nbd.2013.03.014. Epub 2013 Apr 5. Erratum in: Neurobiol Dis. O 2013 Oct;58:191.

PMID:
23567651
4.

Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.

J Neurosci. 2002 Apr 1;22(7):2780-91.

5.

GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A.

Brain. 2011 Aug;134(Pt 8):2302-11. doi: 10.1093/brain/awr149. Epub 2011 Jun 28.

PMID:
21712347
6.

Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.

Coune PG, Bensadoun JC, Aebischer P, Schneider BL.

J Parkinsons Dis. 2011;1(4):373-87. doi: 10.3233/JPD-2011-11058.

PMID:
23939344
7.

Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.

Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A.

Neurobiol Dis. 2012 Mar;45(3):939-53. doi: 10.1016/j.nbd.2011.12.013. Epub 2011 Dec 11.

PMID:
22182688
8.

Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.

Hayashita-Kinoh H, Yamada M, Yokota T, Mizuno Y, Mochizuki H.

Biochem Biophys Res Commun. 2006 Mar 24;341(4):1088-95. Epub 2006 Jan 25.

PMID:
16460685
9.

Generation of a alpha-synuclein-based rat model of Parkinson's disease.

Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD, Giusti P.

Neurobiol Dis. 2008 Apr;30(1):8-18. doi: 10.1016/j.nbd.2007.11.002. Epub 2007 Nov 13.

PMID:
18313315
10.

Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.

Moloney TC, Hyland R, O'Toole D, Paucard A, Kirik D, O'Doherty A, Gorman AM, Dowd E.

CNS Neurosci Ther. 2014 Jan;20(1):50-8. doi: 10.1111/cns.12200. Epub 2013 Nov 27.

PMID:
24279716
11.

Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.

Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L.

Brain. 2013 Jul;136(Pt 7):2130-46. doi: 10.1093/brain/awt131. Epub 2013 Jun 11.

PMID:
23757764
12.

Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.

Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH, Bartus RT.

Neurosurgery. 2009 Apr;64(4):602-12; discussion 612-3. doi: 10.1227/01.NEU.0000340682.06068.01.

PMID:
19349823
13.

α-Synuclein expression is modulated at the translational level by iron.

Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M.

Neuroreport. 2012 Jun 20;23(9):576-80. doi: 10.1097/WNR.0b013e328354a1f0.

PMID:
22581044
14.

Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.

Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T.

J Neurosci. 2011 Nov 16;31(46):16884-94. doi: 10.1523/JNEUROSCI.3967-11.2011.

15.

Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.

Decressac M, Mattsson B, Björklund A.

Exp Neurol. 2012 May;235(1):306-15. doi: 10.1016/j.expneurol.2012.02.012. Epub 2012 Feb 25.

PMID:
22394547
16.

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.

Brain. 2005 Nov;128(Pt 11):2654-64. Epub 2005 Jul 6.

PMID:
16000336
17.

Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons.

Aldrin-Kirk P, Davidsson M, Holmqvist S, Li JY, Björklund T.

PLoS One. 2014 Jul 7;9(7):e100869. doi: 10.1371/journal.pone.0100869. eCollection 2014.

18.

Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.

Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M.

Eur J Neurosci. 2010 Aug;32(3):409-22. doi: 10.1111/j.1460-9568.2010.07284.x.

PMID:
20704592
19.

α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.

Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M.

J Neuropathol Exp Neurol. 2013 Jul;72(7):624-45. doi: 10.1097/NEN.0b013e31829768d2.

PMID:
23771222
20.

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. Epub 2002 Jul 16.

Supplemental Content

Support Center